SAN JOSE, Calif., Jan. 28, 2020 /PRNewswire/ -- Aridis
Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company") presented a
comprehensive profile of its APEX™ platform
technology at the antibody and cell engineering conference
19th Annual PepTalk: The Protein Science Week on
Friday, January 24, 2020 in
San Diego, CA USA.
To access the presentation, please visit the "Publications and
Posters" page within the Investors section of the Aridis
Pharmaceuticals website at
https://investors.aridispharma.com/overview.
The APEX™ is a platform for the unbiased discovery
of new and highly potent antibodies against pathogens and a
methodology to maximize the production/yield of selected antibodies
on commercial scale. The platform technology is comprised of a
silicon wafer-based array of nanoliter sized tissue microculture
wells that enable rapid screening of antibody secreting cells,
enabling discovery of potent antibodies against targets such as
viruses within one day of a pandemic outbreak. It also
features CRISPR enabled activation of endogenous genetic control
elements that dramatically increase the yield of biotherapeutic
drugs from manufacturing production cell lines, and a proprietary
production cell line that is designed to rapidly manufacture
multiple monoclonal antibody therapeutics at approximately half the
manufacturing cycle time than current available manufacturing
technologies.
"We believe that APEX™ will provide our life
sciences industry partners with significant monoclonal antibody
discovery and manufacturing benefits, and we see a great future
with this technology as a key growth driver," commented Dr.
Vu Truong, Chief Executive Officer
of Aridis Pharmaceuticals.
APEX™ is expected to facilitate the rapid
discovery and production of critical therapies for companies
operating in the biopharmaceutical, biomanufacturing and biosimilar
space. Aridis is planning to host an analyst day to profile
APEX™ and its potential as a service business to
investors and analysts in the spring of 2020.
For analysts and investors wishing to be first notified of the
date for our upcoming analyst day, please contact us at
info@aridispharma.com.
Information about the PepTalk Conference can be found at:
http://www.chi-peptalk.com.
About CRISPR and Gene Editing
"CRISPR" stands for Clustered Regularly Interspaced Short
Palindromic Repeats, which refers to a genome engineering technique
that uses bacterial enzymes such as Cas9, Cas12a, CPF-1, etc. to
modify genes (e.g. activate, inhibit, edit) in living cells and
organisms. These enzymes can be programmed to target specific
stretches of genetic code and to edit DNA at precise locations or
to influence the expression of a gene product. CRISPR is being used
in therapeutic settings to correct mutations at specific locations
in the human genome in order to treat genetic causes of
diseases.
About Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc. discovers and develops anti-infectives
to be used as add-on treatments to standard-of-care antibiotics.
The Company is utilizing its proprietary APEX™ and
MabIgX® technology platforms to rapidly identify rare, potent
antibody-producing B-cells from patients who have successfully
overcome an infection, and to manufacture mAbs for therapeutic
treatment of critical infections. These mAbs are already of human
origin and functionally optimized for high potency by the donor's
immune system; hence, they do not require genetic engineering or
further optimization to achieve full functionality.
The Company has generated multiple clinical stage mAbs targeting
bacteria that cause life-threatening infections such as
VAP and HAP. The use of mAbs as anti-infective treatments
represents an innovative therapeutic approach that harnesses the
human immune system to fight infections and is designed to overcome
the deficiencies associated with the current standard of care which
is broad spectrum antibiotics. Such deficiencies include, but are
not limited to, increasing drug resistance, short duration of
efficacy, disruption of the normal flora of the human microbiome
and lack of differentiation among current treatments. The mAb
portfolio is complemented by a non-antibiotic novel mechanism small
molecule anti-infective candidate being developed to treat lung
infections in cystic fibrosis patients. The company's pipeline is
highlighted below:
Aridis' Pipeline
AR-301 (VAP). AR-301 is a fully human
immunoglobulin 1, or IgG1, mAb currently in Phase 3 clinical
development targeting gram-positive S.
aureus alpha-toxin in VAP patients.
AR-101 (HAP). AR-101 is a fully human
immunoglobulin M, or IgM, mAb targeting P.
aeruginosa liposaccharides serotype O11, which accounts
for approximately 22% of all P.
aeruginosa hospital acquired pneumonia cases
worldwide.
AR-501 (cystic fibrosis). AR-501 is an inhaled
formulation of gallium citrate with broad-spectrum anti-infective
activity being developed to treat chronic lung infections in cystic
fibrosis patients. This program is currently in a Phase 1/2a
clinical study in healthy volunteers and CF patients.
AR-401 (blood stream infections). AR-401 is a
fully human mAb preclinical program aimed at treating infections
caused by gram-negative Acinetobacter baumannii.
AR-201 (RSV infection). AR-201 is a fully human IgG1
mAb preclinical program aimed at neutralizing diverse clinical
isolates of respiratory syncytial virus (RSV).
For additional information on Aridis Pharmaceuticals, please
visit https://aridispharma.com/.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties.
These statements may be identified by the use of words such as
"anticipate," "believe," "forecast," "estimated" and "intend" or
other similar terms or expressions that concern Aridis'
expectations, strategy, plans or intentions. These forward-looking
statements are based on Aridis' current expectations and actual
results could differ materially. There are a number of
factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. These
factors include, but are not limited to, the timing of regulatory
submissions, Aridis' ability to obtain and maintain regulatory
approval of its existing product candidates and any other product
candidates it may develop, approvals for clinical trials may be
delayed or withheld by regulatory agencies, risks relating to the
timing and costs of clinical trials, risks associated with
obtaining funding from third parties, management and employee
operations and execution risks, loss of key personnel, competition,
risks related to market acceptance of products, intellectual
property risks, risks associated with the uncertainty of future
financial results, Aridis' ability to attract collaborators and
partners and risks associated with Aridis' reliance on third party
organizations. While the list of factors presented here is
considered representative, no such list should be considered to be
a complete statement of all potential risks and uncertainties.
Unlisted factors may present significant additional obstacles to
the realization of forward-looking statements. Actual results could
differ materially from those described or implied by such
forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption "Risk Factors" in Aridis' 10-K
for the year ended December 31,
2018 and Aridis' other filings made with the Securities and
Exchange Commission. Forward-looking statements included herein are
made as of the date hereof, and Aridis does not undertake any
obligation to update publicly such statements to reflect subsequent
events or circumstances.
Contact:
Investor Relations
Jason Wong
Blueprint Life Science Group
jwong@bplifescience.com
(415) 375-3340 Ext. 4
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aridis-pharmaceuticals-presents-apex-antibody-discovery-and-production-platform-technology-at-the-19th-annual-chi-peptalk-conference-300994762.html
SOURCE Aridis Pharmaceuticals, Inc.